NUBEQA (darolutamide) tablets, for oral use. Initial U.S. Approval: 2019

Category: .

NUBEQA (darolutamide) tablets, for oral use. Initial U.S. Approval: 2019

INDICATIONS AND USAGE
NUBEQA is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.
DOSAGE FORMS & STRENGTHS
Tablets: 300 mg
Manufactured By: Bayer
Prescribing Information URL: Click Here

Access to NUBEQA (darolutamide) tablets: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Darolutamide, sold under the brand name Nubeqa, is an antiandrogen medication which is used in the treatment of non-metastatic castration-resistant prostate cancer in men. It is specifically approved to treat non-metastatic castration-resistant prostate cancer (nmCRPC) in conjunction with surgical or medical castration. The medication is taken by mouth twice per day with food.
Darolutamide was patented in 2011, and was approved for medical use in July 2019. It was approved for medical use in the European Union in March 2020,and in Australia in July 2020.

Reviews

There are no reviews yet.

Add a review

neeraj
Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.